Clinical Trials Browser

Breast Neoplasms

NCT04873362 2026-03-04

Astefania

Phase 3 Active not recruiting

1,188 enrolled

Breast

Breast Neoplasms

NCT05000294 2026-02-18

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

Phase 1/2 Suspended

29 enrolled

BreastEndocrineGastrointestinalGenitourinaryGynecologicNETSarcoma

Bile Duct Neoplasms, Breast Neoplasms, Gallbladder Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Vulvar Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT02530489 2026-02-17

Nab-Paclitaxel and Atezolizumab Before Surgery in Treating Patients With Triple Negative Breast Cancer

Phase 2 Completed

37 enrolled 8 charts

Breast

Triple Negative Breast Neoplasms

NCT04158258 2026-02-12

A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin America

Active not recruiting

2,907 enrolled

Breast

Breast Neoplasms

NCT05092373 2026-01-14

Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax

Phase 1 Recruiting

43 enrolled

BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Carcinoma, Hepatocellular, Ovarian Neoplasms, Endometrial Neoplasms

NCT04770272 2026-01-12

neoMono

Phase 2 Terminated

442 enrolled 42 charts

Breast

Triple Negative Breast Neoplasms

NCT06690840 2026-01-05

AZALEA

Phase 2 Recruiting

45 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03199885 2025-12-30

Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer

Phase 3 Completed

190 enrolled 12 charts

Breast

Breast Neoplasms

NCT04148911 2025-12-26

EL1SSAR

Phase 3 Completed

184 enrolled 15 charts

Breast

Triple Negative Breast Neoplasms

NCT03202316 2025-12-16

Atezolizumab, Cobimetinib, and Eribulin in Treating Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer

Phase 2 Active not recruiting

37 enrolled

Breast

Inflammatory Breast Neoplasms

NCT03483012 2025-12-09

Atezolizumab + Stereotactic Radiation in Triple-negative Breast Cancer and Brain Metastasis

Phase 2 Active not recruiting

6 enrolled 19 charts

Breast

Breast Neoplasms

NCT05180006 2025-12-01

BIS-Program

Phase 2 Terminated

33 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01898117 2025-11-26

Triple-B

Phase 2 Active not recruiting

304 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT02849496 2025-11-24

Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer

Phase 2 Active not recruiting

81 enrolled

Breast

Breast Neoplasms

NCT03371017 2025-11-12

IMpassion132

Phase 3 Completed

595 enrolled 37 charts

Breast

Triple Negative Breast Neoplasms

NCT03280563 2025-11-10

MORPHEUS HR+BC

Phase 1/2 Completed

144 enrolled 25 charts

Breast

Breast Neoplasms

NCT02883062 2025-10-16

Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer

Phase 2 Active not recruiting

67 enrolled 16 charts

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04954599 2025-10-07

Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI

Phase 1/2 Recruiting

126 enrolled

BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Triple Negative Breast Neoplasms

NCT04273061 2025-09-22

CAPTIV-8

Phase 2 Recruiting

200 enrolled

BreastDermatologicGastrointestinalHead & NeckSarcomaThoracic

Breast Neoplasms, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Neoplasms, Unknown Primary, Sarcoma, Skin Neoplasms, Urogenital Neoplasms

NCT03802604 2025-09-09

PROMETEO

Phase EARLY_PHASE1 Completed

28 enrolled

Breast

Breast Neoplasms

NCT04759248 2025-09-09

ATREZZO

Phase 2 Active not recruiting

55 enrolled

Breast

Breast Neoplasms, Neoplasms

NCT04434040 2025-08-19

Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

Phase 2 Recruiting

40 enrolled

Breast

Breast Neoplasms, Neoplasm, Residual, Triple Negative Breast Neoplasms

NCT03170960 2025-08-17

Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors

Phase 1 Active not recruiting

914 enrolled

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT03568656 2025-08-08

Study to Evaluate CCS1477 in Advanced Tumours

Phase 1/2 Completed

220 enrolled

BreastThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT04740918 2025-08-08

KATE3

Phase 3 Terminated

96 enrolled 16 charts

Breast

Breast Neoplasms

NCT03289962 2025-07-04

A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors

Phase 1 Completed

272 enrolled

BreastDermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Kidney Neoplasms, Melanoma, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT06067061 2025-06-11

neoBREASTIM

Phase 1/2 Terminated

2 enrolled

Breast

Triple Negative Breast Neoplasms

NCT03417544 2025-04-02

Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC

Phase 2 Active not recruiting

19 enrolled 26 charts

BreastCNS

HER2-positive Metastatic Breast Cancer

Clinical Trials

Morpheus-panBC

Astefania

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

Nab-Paclitaxel and Atezolizumab Before Surgery in Treating Patients With Triple Negative Breast Cancer

A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin America

Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax

neoMono

AZALEA

Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer

EL1SSAR

Atezolizumab, Cobimetinib, and Eribulin in Treating Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer

Atezolizumab + Stereotactic Radiation in Triple-negative Breast Cancer and Brain Metastasis

BIS-Program

Triple-B

Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer

IMpassion132

MORPHEUS HR+BC

Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer

Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI

CAPTIV-8

PROMETEO

ATREZZO

Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors

Study to Evaluate CCS1477 in Advanced Tumours

KATE3

A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors

neoBREASTIM

Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC